Page results
-
Info on the support available to independent for people affected by cancer or a blood condition.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
Read more about the Halcyon linear accelerator, aimed at making cancer treatment faster, more comfortable, and more precise for patients.
-
UCL and UCLH researchers have developed an artificial intelligence-based tool that can assess a patient’s brain tumour scan and provide greater patient-personalised detail to aid their treatment.
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.
-
UCLH Charity is delighted to announce a generous £1.5 million donation from the Bukhman Philanthropies.
-
UCLH’s trial of the world’s first ‘gene silencing’ drug for Alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.